无组织与肿瘤信息ctDNA检测早期三阴性乳腺癌分子残留病灶
该研究基于c-TRAK TN试验,对159例中高复发风险三阴性乳腺癌患者进行无组织ctDNA检测,发现无组织ctDNA阳性与复发风险显著相关(HR 27.2),且与肿瘤信息检测一致性良好,中位领先时间相当。
要点
- 无组织ctDNA检测在34.0%患者中阳性,与复发风险强相关(HR 27.2)。
- 与dPCR相比,无组织检测中位领先时间更长(7.9 vs 5.8个月)。
- 与多变异肿瘤信息检测相比,中位领先时间无显著差异(7.6 vs 7.1个月)。
核心结论
- 无组织ctDNA检测在TNBC监测中具有强预后价值,支持在组织不可及时开展MRD检测。
研究设计与样本
- 研究为c-TRAK TN多中心2期试验的预后与探索性分析,纳入159例中高复发风险TNBC患者。
- 每3个月采集血浆样本,持续至辅助治疗后2年,共分析1026份样本。
主要发现
- 无组织ctDNA检测阳性患者54例(34.0%),与复发风险显著相关(HR 27.2;95%CI 13.7-54.2;P<.001)。
- 无组织检测与dPCR均阳性者42例(26%),其中14例(33.3%)无组织检测更早,dPCR更早者0例。
- 无组织检测中位领先时间7.9个月(95%CI 6.1-10.5),dPCR为5.8个月(95%CI 3.3-10.0);HR 0.57;95%CI 0.34-0.95;P=.03。
- 与多变异肿瘤信息检测均阳性者41/133例,其中12例(29.3%)肿瘤信息检测更早,1例(2.4%)无组织检测更早。
- 无组织检测与多变异肿瘤信息检测中位领先时间分别为7.6个月(95%CI 4.6-10.5)和7.1个月(95%CI 5.7-10.0);HR 1.46;95%CI 0.87-2.44;P=.15。
临床怎么用
- 无组织ctDNA检测可用于TNBC辅助治疗后监测,尤其在组织样本不可及时提供MRD信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Molecular residual disease (MRD) detection has potential to transform the selection of adjuvant therapy. Most evidence is from tumor-informed assays. Tissue-free assays not requiring sequencing of the primary tumor may simplify workflows if they offer accuracy similar to that of tumor-informed assays. OBJECTIVE: To evaluate tissue-free circulating tumor DNA (ctDNA) analysis in patients with triple negative breast cancer (TNBC) and compare the tissue-free assay with tumor-informed assay results. DESIGN, SETTING, AND PARTICIPANTS: This was a prognostic and exploratory analysis of patients with TNBC at moderate to high risk of recurrence who were participating in the ctDNA surveillance period of c-TRAK TN, a multicenter phase 2 clinical study. Plasma samples were collected from participants every 3 months for up to 2 years after the completion of adjuvant therapy and analyzed prospectively with digital polymerase chain reaction (dPCR). Data for the analysis were from a database lock on September 28, 2021, with subsequent follow-up through January 18, 2023. Data were analyzed from July 2025 to May 2026. INTERVENTION OR EXPOSURE: Tissue-free assay leverages cancer differential methylation patterns to detect ctDNA. MAIN OUTCOME AND MEASURES: Recurrence-free survival by tissue-free ctDNA detection status. Comparison between tissue-free ctDNA detection and both dPCR and whole-exome sequencing-powered multivariant tumor-informed assays. RESULTS: The analysis included 1026 plasma samples from 159 patients (mean [SD; range] age, 51.4 [11.4; 25.0-78.0] years; 159 females [100%]). The tissue-free assay detected ctDNA in 54 patients (34.0%), with detection strongly associated with risk of recurrence (HR, 27.2; 95% CI, 13.7-54.2; P < .001). Among patients with ctDNA detected by both the tissue-free assay and dPCR (42 patients [26%]), tissue-free detection occurred at an earlier time point in 14 patients (33.3%); dPCR detection occurred before tissue-free detection in no patients. Median lead time to recurrence was 7.9 (95% CI, 6.1-10.5) months for tissue-free vs 5.8 (95% CI, 3.3-10.0) months for dPCR (HR, 0.57; 95% CI, 0.34-0.95; P = .03). Concordance between tissue-free and multivariant tumor-informed assays was good. Among patients detected by both assays (41 of 133), 12 of 41 (29.3%) had ctDNA detected earlier by multivariant tumor-informed assay with 1 (2.4%) earlier by the tissue-free assay. Median lead times to recurrence were 7.6 (95% CI, 4.6-10.5) months with tissue-free and 7.1 (95% CI, 5.7-10.0) months with multivariant tumor-informed assay (HR, 1.46; 95% CI, 0.87-2.44; P = .15). CONCLUSION AND RELEVANCE: In this prognostic study, tissue-free ctDNA detection during surveillance was strongly prognostic for recurrence in patients with TNBC. Comparable lead times between the tissue-free and multivariant tumor-informed assays support tissue-free MRD detection in a clinical trial setting, permitting ctDNA testing when tissue is not available.
引用
- Cunningham N, Cutts RJ, Swift C, et al. Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer. JAMA Oncol. 2026. PMID: 42593771. doi:10.1001/jamaoncol.2026.2833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。